Survival outcomes according to urine FLC and sFLC characteristics at the end of induction therapy. PFS for patients with (A) negative vs positive UPEP (median PFS, 47 and 36 months, respectively), (B) normal vs elevated iFLC (median PFS, not reached and 36 months, respectively), (C) negative vs positive uIFE (median PFS, 47 and 36 months, respectively), and (D) normal vs abnormal κ:λ sFLC ratio (median PFS, not reached and 34 months, respectively). OS for patients with (E) negative vs positive uIFE (median OS not reached for both) and (F) normal vs abnormal κ:λ sFLC ratio (median OS not reached for both). P values calculated by log-rank test. Number of patients (events) for each arm is indicated. Comparisons include patients with matched urine and serum data.